KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Cash (2016 - 2025)

Pfizer (PFE) has disclosed Change in Cash for 17 consecutive years, with -$196.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash changed N/A to -$196.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $91.0 million for FY2025, 105.03% up from the prior year.
  • Change in Cash for Q4 2025 was -$196.0 million at Pfizer, up from -$301.0 million in the prior quarter.
  • The five-year high for Change in Cash was $1.8 billion in Q2 2023, with the low at -$2.1 billion in Q1 2024.
  • Average Change in Cash over 5 years is -$60.2 million, with a median of $209.0 million recorded in 2021.
  • The sharpest move saw Change in Cash soared 3626.67% in 2022, then tumbled 429.91% in 2024.
  • Over 5 years, Change in Cash stood at $209.0 million in 2021, then plummeted by 409.09% to -$646.0 million in 2022, then surged by 51.08% to -$316.0 million in 2023, then crashed by 458.54% to -$1.8 billion in 2024, then surged by 88.9% to -$196.0 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$196.0 million, -$301.0 million, and $213.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.